Leukocyte Interleukin, Injection 200IU + Leukocyte Interleukin, injection 400IU
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Condyloma
Conditions
Condyloma
Trial Timeline
Apr 1, 2014 → Jan 1, 2016
NCT ID
NCT02115919About Leukocyte Interleukin, Injection 200IU + Leukocyte Interleukin, injection 400IU
Leukocyte Interleukin, Injection 200IU + Leukocyte Interleukin, injection 400IU is a phase 1 stage product being developed by CEL-SCI for Condyloma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02115919. Target conditions include Condyloma.
What happened to similar drugs?
0 of 1 similar drugs in Condyloma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02115919 | Phase 1 | Terminated |
Competing Products
2 competing products in Condyloma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine + Comparator: placebo (unspecified) | Merck | Phase 3 | 40 |
| AP611074 5% gel + AP611074 matching placebo | Vaxart | Phase 2 | 25 |